



- (51) **International Patent Classification:**
A61K 38/46 (2006.01) *A61P 25/28* (2006.01)
A61K 48/00 (2006.01) *C12N 15/52* (2006.01)
A61P 25/08 (2006.01) *C12N 15/86* (2006.01)
- (21) **International Application Number:**
PCT/US2024/020571
- (22) **International Filing Date:**
19 March 2024 (19.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/491,205 20 March 2023 (20.03.2023) US
63/584,000 20 September 2023 (20.09.2023) US
63/600,153 17 November 2023 (17.11.2023) US
- (71) **Applicant: SPARK THERAPEUTICS, INC.** [US/US];
3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US).
- (72) **Inventors: ALAM, Suhail;** C/o Spark Therapeutics, Inc.,
3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **BIFERI, Maria, Grazia;** C/o Spark Therapeutics,
Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **COHEN, Daniel;** C/o Spark Therapeutics,
Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **EVANS, James, Perry;** C/o Spark Therapeu-
tics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **KHATIWADA, Apeksha;** C/o Spark Thera-
peutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **MCBRIDE, Jodi;** C/o Spark Therapeu-
tics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). **RAMSBURG, Elizabeth;** C/o Spark Thera-
peutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US).
- (74) **Agent: HEBER, Sheldon et al.;** ICE MILLER LLP, 1735
Market Street, Suite 3900, Philadelphia, PA 19103 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*
- Published:**
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
- (88) **Date of publication of the international search report:**
23 January 2025 (23.01.2025)

(54) **Title:** PPT1 GENE THERAPY




FIG. 1

(57) **Abstract:** The present invention features PPT1 polypeptides and encoding nucleic acid constructs. Uses of the polypeptides and encoding nucleic acid constructs include producing PPT1 polypeptides, increasing PPT1 activity in a subject; and treating a PPT1 related disorder, such as CLN1 disease in a subject.